Prosecution Insights
Last updated: October 04, 2026

Changsha Magill Medical Technology Co. Ltd.

Technology area: Medical Devices & Mechanical Engineering

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Analysis

Changsha Magill Medical Technology Co. Ltd. currently manages 1 pending office action within the Medical Devices & Mechanical Engineering technology area. This 1 pending office action is being handled by 1 distinct examiner, which centralizes the prosecution process for the company's current intellectual property. The application is assigned to 1 distinct art unit, reflecting a specific technical focus for the pending innovation within the medical device field.

STIMPERT, PHILIP EARL is the busiest examiner for the company, overseeing 1 busiest examiner pending office action. This individual is responsible for the 1 busiest examiner pending office action currently active for the portfolio. Consequently, the company's immediate prosecution success is entirely dependent on the decisions and timelines of this 1 distinct examiner within the 1 distinct art unit.

For a patent practitioner, this concentration means that the prosecution strategy should be highly tailored to the specific tendencies of STIMPERT, PHILIP EARL. Since there is only 1 distinct art unit involved, there is no opportunity to compare examination styles across different units for this portfolio. The singular nature of the matters in the Medical Devices & Mechanical Engineering technology area simplifies the management of the portfolio but increases the impact of a single examiner's perspective.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

0
Life Sciences
0% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
100% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
STIMPERT, PHILIP EARL 1 63.1% +48.8%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17920068 INFUSION BOX OF INFUSION APPARATUS, INFUSION APPARATUS, AND INFUSION PUMP STIMPERT, PHILIP EARL 13d

Top Art Units

Art UnitApps
3783 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17920068 INFUSION BOX OF INFUSION APPARATUS, INFUSION APPARATUS, AND INFUSION PUMP STIMPERT, PHILIP EARL 3783 §103 Final Rejection 13d Pending Oct 20, 2022

Managing Changsha Magill Medical Technology Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month